Evidence map›Paper›PMID 41863805›Full record

ArticleCell reports2026

Autoinhibitory control of MLKL governs pseudokinase domain phosphorylation and oligomerization during necroptosis.

Michelle J Pan, Derek W Abbott

Abstract read
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michelle J PanDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Derek W AbbottDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Department of Immunology and Genomic Medicine, National Jewish Hospital, Denver, CO 80206, USA. Electronic address: abbottd@njhealth.org.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Innate Immune Signal Transduction Specificity in Inflammatory DiseaseR35GM141603 · NIGMS · NATIONAL JEWISH HEALTH · PI Derek W Abbott · 2021 to 2026
$1.9M
NIGMS NIH HHS R35 GM141603NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Necroptotic cell death triggers the release of inflammatory mediators but the exact mechanisms controlling its activation are not fully understood. Previous studies have identified key steps during necroptosis, which are believed to be coupled: MLKL phosphorylation by RIPK3, release of N-terminal autoinhibition, and MLKL oligomerization. Yet, ectopic expression of phosphomimetic MLKL is insufficient to induce necroptosis in human cells. Here, we employ five different pharmacological, biological, and genetic methods to demonstrate that inhibiting the MLKL N terminus prevents both phosphorylation and oligomerization. Conversely, loss of interaction between the N-terminal four-helical bundle and brace domains demonstrates basal MLKL phosphorylation, even in the absence of necroptotic stimuli. Moreover, we show that MLKL phosphorylation is not necessary for maintaining MLKL oligomer stability. We propose that MLKL is released from autoinhibition prior to phosphorylation, explaining why phosphomimetic MLKL lacks cytotoxic activity.

Indexed as

autoinhibitioncell deathCP: immunologycytotoxicitykinaseMLKLnecroptosisoligomerizationpseudokinaseRIPK1RIPK3

Identifiers

PMID41863805
PMCPMC13180255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.